ResearcherBeijing University of Chemical TechnologyActive in the last 2 years

Xing Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9990-1479; OpenAlex author ID A5100365513. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Antibiotic-drug conjugates: Enhancing chemo-immunotherapy of gemcitabine for pancreatic cancer by eliminating intratumoral bacteria. Last author DOI 10.1016/j.biomaterials.2026.124368 ↗
Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bacteria. Last author DOI 10.1002/adma.202206765 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ziyao Zhang · 1 shared paper, 2026 · strength 0.29
- Paper Antibiotic-drug conjugates: Enhancing chemo-immunotherapy of gemcitabine for pancreatic cancer by eliminating intratumo… DOI 10.1016/j.biomaterials.2026.124368 ↗
Yingjie Yu · 1 shared paper, 2022 · strength 0.15
- Paper Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bac… DOI 10.1002/adma.202206765 ↗
Xiaoxu Kang · 1 shared paper, 2022 · strength 0.15
- Paper Dual-Cascade Responsive Nanoparticles Enhance Pancreatic Cancer Therapy by Eliminating Tumor-Resident Intracellular Bac… DOI 10.1002/adma.202206765 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.